Get the Stockscreener App
24.23
2.67%
0.63
After Hours:
23.32
-0.91
-3.76%
Zymeworks Inc. stock is traded at $24.23, with a volume of 522.23K.
It is up +2.67% in the last 24 hours and up +0.46% over the past month.
Zymeworks Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of bio-therapeutics for the treatment of cancer in Canada. The company's lead product candidate is ZW25, a novel bispecific antibody that is in Phase I clinical trial for the treatment of breast and gastric cancer. It is also developing ZW49, a bispecific antibody-drug conjugate that is in IND application stage. The company has strategic partnerships with Merck Sharp & Dohme Research Ltd.; Eli Lilly and Company; Celgene Corporation and Celgene Alpine Investment Co. LLC; GlaxoSmithKline Intellectual Property Development Limited; Daiichi Sankyo Co., Ltd.; and Janssen Biotech, Inc., as well as a collaboration agreement with Celgene Corporation. It also has licensing and research collaboration with LEO Pharma A/S to discover and develop bispecific antibodies targeting cytokine-receptor pathways. Zymeworks Inc. was founded in 2003 and is headquartered in Vancouver, Canada.
See More
Previous Close:
$23.60
Open:
$23.96
24h Volume:
522.23K
Relative Volume:
0.71
Market Cap:
$1.80B
Revenue:
$105.97M
Net Income/Loss:
$-81.13M
P/E Ratio:
-22.45
EPS:
-1.0791
Net Cash Flow:
$-35.43M
1W Performance:
+3.33%
1M Performance:
+0.46%
6M Performance:
+49.94%
1Y Performance:
+89.30%
1-Day Range:
$23.96
$24.82
1-Week Range:
$23.08
$24.82
52-Week Range:
$9.03
$28.49
Zymeworks Inc. Stock (ZYME) Company Profile
Name
Zymeworks Inc.
Sector
Industry
Phone
604-678-1388
Address
1385 West 8th Avenue, Suite 540, Vancouver, BC
Compare ZYME vs VRTX, REGN, ALNY, ARGX, INSM
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ZYME
Zymeworks Inc.
|
24.23 | 1.75B | 105.97M | -81.13M | -35.43M | -1.0791 |
VRTX
Vertex Pharmaceuticals Inc
|
454.97 | 113.96B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
749.47 | 78.41B | 14.34B | 4.50B | 3.77B | 41.56 |
ALNY
Alnylam Pharmaceuticals Inc
|
328.70 | 40.85B | 3.71B | 313.75M | 465.38M | 2.2571 |
ARGX
Argen X Se Adr
|
697.05 | 42.05B | 4.16B | 1.29B | 734.26M | 19.58 |
INSM
Insmed Inc
|
148.31 | 29.99B | 606.42M | -1.28B | -997.58M | -6.403 |
Zymeworks Inc. Stock (ZYME) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-12-25 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Dec-03-25 | Initiated | Citizens JMP | Mkt Outperform |
| Oct-24-25 | Resumed | Wells Fargo | Equal Weight |
| Oct-14-25 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Oct-10-25 | Initiated | B. Riley Securities | Buy |
| May-20-25 | Initiated | TD Cowen | Buy |
| Dec-16-24 | Upgrade | JP Morgan | Neutral → Overweight |
| Nov-07-24 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Nov-01-24 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Mar-21-23 | Resumed | Wells Fargo | Overweight |
| Jan-04-23 | Reiterated | H.C. Wainwright | Neutral |
| Dec-20-22 | Upgrade | Jefferies | Hold → Buy |
| Nov-01-22 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Oct-21-22 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Oct-04-22 | Resumed | Wells Fargo | Overweight |
| May-05-22 | Upgrade | Guggenheim | Neutral → Buy |
| Mar-15-22 | Initiated | Evercore ISI | Outperform |
| Dec-10-21 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| Nov-17-21 | Resumed | Guggenheim | Neutral |
| Oct-07-21 | Initiated | Jefferies | Hold |
| Mar-31-21 | Initiated | Credit Suisse | Outperform |
| Feb-25-21 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Feb-08-21 | Resumed | H.C. Wainwright | Buy |
| Jan-25-21 | Downgrade | Citigroup | Buy → Neutral |
| Sep-29-20 | Resumed | JP Morgan | Neutral |
| Aug-06-20 | Initiated | SVB Leerink | Outperform |
| Jan-10-20 | Initiated | Wolfe Research | Outperform |
| Dec-09-19 | Initiated | JP Morgan | Neutral |
| Nov-25-19 | Initiated | H.C. Wainwright | Buy |
| Nov-20-19 | Initiated | Guggenheim | Buy |
| Sep-30-19 | Upgrade | Raymond James | Outperform → Strong Buy |
| Aug-30-19 | Initiated | Stifel | Buy |
| Jul-18-19 | Initiated | Deutsche Bank | Buy |
| May-11-18 | Upgrade | Barclays | Underweight → Equal Weight |
| Mar-19-18 | Initiated | Raymond James | Outperform |
View All
Zymeworks Inc. Stock (ZYME) Latest News
Tranche Update on Zymeworks Inc.'s Equity Buyback Plan announced on November 18, 2025. - marketscreener.com
Zymeworks Inc stock faces renewed scrutiny amid biotech sector volatility and pipeline updates - AD HOC NEWS
Zymeworks Announces Participation in Upcoming Investor Conferences - Sahm
Aug Weekly: Does Zymeworks Inc stock have upside surprise potentialGap Up & Safe Swing Trade Setup Alerts - baoquankhu1.vn
Zymeworks to Highlight Pipeline and Asset Strategy at Key Investor Conferences - TipRanks
Zymeworks executives head to two April healthcare investor events - Stock Titan
Published on: 2026-03-23 15:16:44 - baoquankhu1.vn
Zymeworks Inc. (ZYME) reports Q4 loss, lags revenue estimates - MSN
Zymeworks Inc stock faces biotech volatility amid pipeline updates and market shifts - AD HOC NEWS
Will Zymeworks Inc benefit from rising consumer demand2026 WrapUp & Weekly Market Pulse Updates - baoquankhu1.vn
Zymeworks Highlights New Ziihera Data to Broaden HER2 Cancer Reach - TipRanks
Experimental breast cancer drug shrinks tumors in 6 weeks at AACR 2026 - Stock Titan
Does Zymeworks (ZYME) Pan-RAS ADC Push Reveal a Durable Edge in Targeted Oncology? - Sahm
Zymeworks to Present Clinical and Preclinical Data on ADC Programs Including Novel RAS ADC Platform at AACR Annual Meeting - Koreabizwire
Zymeworks to present clinical data on cancer drug candidate at AACR - Investing.com Australia
Zymeworks to present clinical data on cancer drug candidate at AACR By Investing.com - Investing.com South Africa
Zymeworks Highlights ADC and Novel Pan-RAS Platform Data Ahead of AACR Meeting - TipRanks
Zymeworks to Present Clinical and Preclinical Data on ADC - GlobeNewswire
New cancer drug conjugates aim at tough RAS tumors in Zymeworks data - Stock Titan
A Look At Zymeworks (ZYME) Valuation After New AACR 2026 Antibody Drug Conjugate Pipeline Data - Sahm
Wall Street Analysts See a 76.74% Upside in Zymeworks (ZYME): Can the Stock Really Move This High? - MSN
Prosight Management LP Cuts Stake in Zymeworks Inc. $ZYME - MarketBeat
Value Recap: Does Zymeworks Inc have strong EBITDA marginsTrade Analysis Report & Accurate Buy Signal Notifications - baoquankhu1.vn
Zymeworks (NASDAQ:ZYME) Trading Up 9.7%What's Next? - MarketBeat
Assessing Zymeworks (ZYME) Valuation After Q4 Updates And Improved Clinical And Funding Outlook - Sahm
Zymeworks (ZYME) Price Target Raised to $48 by Evercore ISI Grou - GuruFocus
Will Zymeworks' (ZYME) Wider Losses and ESOP Shelf Offering Recast Its Long-Term Equity Story? - Sahm
Zymeworks (NASDAQ:ZYME) Price Target Raised to $46.00 - MarketBeat
Zymeworks (ZYME) Rating Maintained, Price Target Raised to $46 b - GuruFocus
Q1 Earnings Forecast for Zymeworks Issued By Lifesci Capital - MarketBeat
Zymeworks FY25 Review: From Milestone Volatility To 2026 Upside (NASDAQ:ZYME) - Seeking Alpha
Zymeworks Inc. (NASDAQ:ZYME) Given Average Rating of "Moderate Buy" by Brokerages - MarketBeat
Zymeworks (NASDAQ:ZYME) Trading 2.8% Higher on Analyst Upgrade - MarketBeat
Forecasting The Future: 4 Analyst Projections For Zymeworks - Benzinga
Zymeworks (ZYME) Target Price Raised by Leerink Partners to $58 - GuruFocus
Stifel raises Zymeworks stock price target on royalty deal value By Investing.com - Investing.com Canada
Stifel raises Zymeworks stock price target on royalty deal value - Investing.com
Zymeworks Inc. (NASDAQ:ZYME) Q4 2025 Earnings Call Transcript - Insider Monkey
Citizens reiterates Zymeworks stock rating on strong cash position - Investing.com Nigeria
Citizens reiterates Zymeworks stock rating on strong cash position By Investing.com - Investing.com Australia
Zymeworks Inc (ZYME) Q4 2025 Earnings Call Highlights: Strategic Milestones and Financial Resilience By GuruFocus - Investing.com Canada
Decoding Zymeworks Inc (ZYME): A Strategic SWOT Insight - GuruFocus
Zymeworks secures $250M royalty financing from Royalty Pharma - Investing.com South Africa
Zymeworks (ZYME) Advances with Promising Zanidatamab Results - GuruFocus
Jefferies reiterates Zymeworks stock rating on financing deal By Investing.com - Investing.com Canada
Jefferies reiterates Zymeworks stock rating on financing deal - Investing.com South Africa
Zymeworks (ZYME) Reveals Q4 Revenue Drop and Strategic Focus Shi - GuruFocus
Zymeworks Inc (ZYME) Q4 2025 Earnings Call Highlights: Strategic Milestones and Financial Resilience - GuruFocus
Zymeworks Secures $250 Million Non-Dilutive Royalty-Backed Financing from Royalty Pharma for Ziihera Royalties - Minichart
Zymeworks Inc. (ZYME) Posts Fourth Quarter Loss, Falls Short of Revenue Projections - Bitget
Royalty Pharma and Zymeworks Enter Into $250 Million Royalty-Backed Note Financing - citybiz
Zymeworks Inc. Stock (ZYME) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.82%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):